Zacks Investment Research cut shares of Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) from a strong-buy rating to a hold rating in a report published on Saturday morning.

According to Zacks, “Zeltiq Aesthetics Inc. is a medical technology company engaged in designing, development and commercialization of non-invasive procedures for the reduction of unwanted fat tissue. The Company offers CoolSculpting System and other products to the dermatologists, plastic surgeons, and aesthetic specialists in North America and internationally. Zeltiq Aesthetics Inc. is based in Pleasanton, California. “

ZLTQ has been the topic of several other reports. Maxim Group increased their price objective on Zeltiq Aesthetics from $40.00 to $48.00 and gave the company a buy rating in a research note on Tuesday, August 9th. Stifel Nicolaus increased their price objective on Zeltiq Aesthetics from $38.00 to $52.00 and gave the company a buy rating in a research note on Wednesday, September 21st. Brean Capital reiterated a buy rating on shares of Zeltiq Aesthetics in a research note on Monday, October 24th. Leerink Swann reiterated an outperform rating and issued a $48.00 price objective on shares of Zeltiq Aesthetics in a research note on Thursday, August 25th. Finally, Northcoast Research reiterated a buy rating on shares of Zeltiq Aesthetics in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $42.78.

Shares of Zeltiq Aesthetics (NASDAQ:ZLTQ) opened at 39.41 on Friday. The stock has a market cap of $1.57 billion, a P/E ratio of 50.85 and a beta of 0.89. The firm’s 50-day moving average price is $37.67 and its 200 day moving average price is $33.39. Zeltiq Aesthetics has a 1-year low of $18.41 and a 1-year high of $41.48.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last announced its quarterly earnings data on Wednesday, November 9th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.04. The business had revenue of $95.20 million for the quarter, compared to analysts’ expectations of $90.84 million. Zeltiq Aesthetics had a negative return on equity of 6.45% and a net margin of 9.48%. The company’s revenue for the quarter was up 55.6% compared to the same quarter last year. During the same period last year, the firm earned $0.05 earnings per share. On average, equities analysts expect that Zeltiq Aesthetics will post ($0.12) earnings per share for the current fiscal year.

In other news, VP Sergio Garcia sold 20,000 shares of Zeltiq Aesthetics stock in a transaction dated Monday, October 17th. The stock was sold at an average price of $39.08, for a total transaction of $781,600.00. Following the sale, the vice president now owns 86,241 shares in the company, valued at $3,370,298.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Keith J. Sullivan sold 8,000 shares of Zeltiq Aesthetics stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $33.01, for a total value of $264,080.00. Following the sale, the insider now owns 82,023 shares in the company, valued at approximately $2,707,579.23. The disclosure for this sale can be found here. Insiders own 15.60% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in Zeltiq Aesthetics by 11.3% in the third quarter. BlackRock Inc. now owns 3,265 shares of the company’s stock worth $128,000 after buying an additional 332 shares in the last quarter. PineBridge Investments L.P. raised its position in Zeltiq Aesthetics by 4.9% in the second quarter. PineBridge Investments L.P. now owns 4,103 shares of the company’s stock worth $112,000 after buying an additional 193 shares in the last quarter. Bank of Montreal Can raised its position in Zeltiq Aesthetics by 49.2% in the third quarter. Bank of Montreal Can now owns 4,794 shares of the company’s stock worth $188,000 after buying an additional 1,580 shares in the last quarter. Teacher Retirement System of Texas raised its position in Zeltiq Aesthetics by 26.9% in the second quarter. Teacher Retirement System of Texas now owns 4,884 shares of the company’s stock worth $133,000 after buying an additional 1,036 shares in the last quarter. Finally, Suntrust Banks Inc. bought a new position in Zeltiq Aesthetics during the third quarter worth about $201,000.

Zeltiq Aesthetics Company Profile

ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.

5 Day Chart for NASDAQ:ZLTQ

Receive News & Stock Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related stocks with our FREE daily email newsletter.